The latest price target for Aytu BioPharma (NASDAQ:AYTU) was reported by Maxim Group on August 9, 2023. The analyst firm set a price target for $5.00 expecting AYTU to rise to within 12 months (a possible 259.71% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Aytu BioPharma (NASDAQ:AYTU) was provided by Maxim Group, and Aytu BioPharma initiated their buy rating.

There is no last upgrade for Aytu BioPharma

There is no last downgrade for Aytu BioPharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aytu BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aytu BioPharma was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.

While ratings are subjective and will change, the latest Aytu BioPharma (AYTU) rating was a initiated with a price target of $0.00 to $5.00. The current price Aytu BioPharma (AYTU) is trading at is $1.39, which is within the analyst’s predicted range.